Dichotomy of complement system: Tumorigenesis or destruction.
Cancer
Cancer immunotherapies
Complement system
Tumor immunology
Journal
Immunology letters
ISSN: 1879-0542
Titre abrégé: Immunol Lett
Pays: Netherlands
ID NLM: 7910006
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
30
10
2019
revised:
06
04
2020
accepted:
18
04
2020
pubmed:
26
4
2020
medline:
9
7
2021
entrez:
26
4
2020
Statut:
ppublish
Résumé
Complement system proteins, their regulators and endpoint effector complex significantly promote tumor growth by upregulation of oncogenic growth factors, activation of mitogenic signalling pathways and breakage of normal cell cycle. Contrastingly, complement cascades, initiated by anti-tumor therapeutic antibodies, also play a pivotal role in therapy response. This contradictory role of complement system possibly be a very crucial factor for the outcomes of antibody mediated immunotherapies. Herein, we reviewed the twin role of the complement system in cancer and also the genetic variations in complement system genes. Future studies should be focused on the biomarker discovery for the personalised cancer immunotherapies.
Identifiants
pubmed: 32333965
pii: S0165-2478(19)30548-6
doi: 10.1016/j.imlet.2020.04.013
pii:
doi:
Substances chimiques
Antibodies
0
Antigens, Neoplasm
0
Complement System Proteins
9007-36-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
89-96Informations de copyright
Copyright © 2020 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.